Sanofi clopidogrel aspirin tablets approved in China

Text|Pharmaceutical Mission Hills

Today, China’s National Food and Drug Administration (NMPA) announced that Sanofi’s application for the listing of the 5.

Screenshot source: NMPA official website

From the point of view of the mechanism of action, aspirin is an inhibitor of cyclooxygenase in the process of arachidonic acid metabolism, which can inhibit the synthesis of TXA2.

Studies have shown that aspirin combined with clopidogrel has a significant therapeutic effect on patients with acute cerebral infarction.

According to the "Chinese Expert Consensus on Clopidogrel/Aspirin Monolithic Compound Antiplatelet Therapy" initiated and formulated by the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association in 2021, the results of multiple clinical studies show that clopidogrel/aspirin monolithic compound preparations Its antiplatelet effect is not inferior to single-agent combination therapy, and its tolerance is equivalent

According to the consensus, in addition to efficacy, the special process of clopidogrel/aspirin single-tablet compound preparation can also reduce adverse reactions

According to statistics, the prevalence and mortality of cardiovascular diseases in China are still on the rise

According to Sanofi's public information, the development of a single-tablet compound preparation of clopidogrel/aspirin simplifies the treatment plan

Reference materials:

[1] On October 11, 2021, the drug approval document pending information is released.

[3] Li Biyan, Song Zulan, Chen Yu.